TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck, Pfizer sue to block proposed version of AzaSite

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

MRK $47.80 -$0.15

PFE $29.16 +$0.07

MYL $31.54 -$0.14

at close on MONDAY

Daily Photo Galleries

By Bloomberg News
Tuesday, June 18, 2013, 12:01 a.m.
 

Merck & Co. and Pfizer Inc. sued generic drugmaker Mylan Pharmaceuticals Inc. to block it from selling a copy of AzaSite, an antibiotic eye solution for fighting bacterial conjunctivitis.

Mylan told Pfizer, Merck and InSite Vision Inc. on May 1 that it sought Food and Drug Administration approval to sell a generic version of AzaSite, according to a lawsuit filed on Friday in federal court in Trenton, N.J. The complaint asks a judge to prevent Mylan from entering the market before the patents expire. One ends in 2018, and the other three expire in 2019, according to the FDA website.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Pittsburgh angles to keep Heinz headquarters in merger
  2. Michigan man takes Heinz to court over Dip & Squeeze ketchup packet
  3. Stop foreign dumping, U.S. Steel CEO Longhi tells Congress
  4. Pa. Gas & Electric agrees to $6.8 million settlement of polar vortex claims
  5. Federal Trade Commission cracks down on crooked vehicle sales
  6. Toyota to carry new attitude into production
  7. One secret Facebook doesn’t want you to know
  8. Energy Department OKs loan of $259M to Alcoa to promote clean energy
  9. Court approves LightSquared’s bankruptcy exit plan
  10. Heinz merging with Kraft in mega-deal; headquarters to stay in Pittsburgh
  11. Federal government eyes regulation of payday lending